PFG Advisors Grows Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

PFG Advisors boosted its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBHFree Report) by 4.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,899 shares of the medical equipment provider’s stock after purchasing an additional 84 shares during the quarter. PFG Advisors’ holdings in Zimmer Biomet were worth $231,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of ZBH. Fairfield Bush & CO. purchased a new stake in Zimmer Biomet in the first quarter valued at approximately $111,000. United Bank grew its holdings in Zimmer Biomet by 4.1% in the first quarter. United Bank now owns 11,072 shares of the medical equipment provider’s stock valued at $1,416,000 after purchasing an additional 437 shares during the period. Panagora Asset Management Inc. grew its holdings in Zimmer Biomet by 153.9% in the first quarter. Panagora Asset Management Inc. now owns 9,803 shares of the medical equipment provider’s stock valued at $1,254,000 after purchasing an additional 5,942 shares during the period. Aviva PLC grew its holdings in Zimmer Biomet by 0.4% in the first quarter. Aviva PLC now owns 30,636 shares of the medical equipment provider’s stock valued at $3,918,000 after purchasing an additional 137 shares during the period. Finally, Allianz Asset Management GmbH grew its holdings in Zimmer Biomet by 11.2% in the first quarter. Allianz Asset Management GmbH now owns 41,816 shares of the medical equipment provider’s stock valued at $5,348,000 after purchasing an additional 4,224 shares during the period. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ZBH has been the subject of several research reports. JPMorgan Chase & Co. boosted their price objective on shares of Zimmer Biomet from $115.00 to $125.00 and gave the stock a “neutral” rating in a research note on Friday, February 9th. Raymond James boosted their price objective on shares of Zimmer Biomet from $133.00 to $137.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 3rd. Truist Financial boosted their price objective on shares of Zimmer Biomet from $133.00 to $135.00 and gave the stock a “hold” rating in a research note on Friday, February 9th. Citigroup boosted their price objective on shares of Zimmer Biomet from $134.00 to $140.00 and gave the stock a “neutral” rating in a research note on Wednesday. Finally, Evercore ISI downgraded shares of Zimmer Biomet from an “outperform” rating to an “inline” rating and decreased their price objective for the stock from $135.00 to $125.00 in a research note on Thursday, January 4th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $139.11.

Read Our Latest Stock Report on Zimmer Biomet

Insiders Place Their Bets

In other Zimmer Biomet news, VP Chad F. Phipps sold 26,156 shares of the stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $128.62, for a total transaction of $3,364,184.72. Following the sale, the vice president now directly owns 44,145 shares of the company’s stock, valued at $5,677,929.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.95% of the stock is owned by corporate insiders.

Zimmer Biomet Trading Up 1.2 %

ZBH opened at $130.01 on Thursday. The stock has a market capitalization of $26.71 billion, a PE ratio of 26.59, a P/E/G ratio of 2.38 and a beta of 1.01. The firm’s fifty day moving average price is $126.09 and its 200 day moving average price is $118.36. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.61 and a quick ratio of 0.78. Zimmer Biomet Holdings, Inc. has a 12-month low of $102.00 and a 12-month high of $149.25.

Zimmer Biomet (NYSE:ZBHGet Free Report) last posted its quarterly earnings results on Thursday, February 8th. The medical equipment provider reported $2.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.15 by $0.05. The firm had revenue of $1.94 billion for the quarter, compared to analysts’ expectations of $1.93 billion. Zimmer Biomet had a net margin of 13.85% and a return on equity of 12.79%. The firm’s quarterly revenue was up 6.3% on a year-over-year basis. During the same period in the prior year, the company posted $1.88 earnings per share. As a group, research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.07 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be issued a dividend of $0.24 per share. The ex-dividend date is Wednesday, March 27th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.74%. Zimmer Biomet’s dividend payout ratio (DPR) is 19.63%.

Zimmer Biomet Profile

(Free Report)

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

Read More

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.